Experience of Magnesium and L-Carnitine Combine Use for Correction of Structural and Functional Heart Changes in Type 2 Diabetic Patients with End-Stage Kidney Disease
DOI:
https://doi.org/10.12775/JEHS.2020.10.12.029Keywords
hemodialysis, diabetic kidney disease, heart remodeling, calcification of mitral and aortic valve, carotid intima-media thickness, progression, magnesium aspartate, L-carnitineAbstract
Introduction and purpose: It is important today to develop new pathogenetic strategies to reduce cardiovascular risk in type 2 diabetic patients with end-stage kidney disease (ESKD). The purpose of the study was to evaluate the efficacy of combine use of magnesium aspartate and L-Carnitine on character of heart changes in dynamics of complex treatment of the patients with diabetic kidney disease (DKD) undergoing hemodialysis (HD). Material and methods: 42 type 2 diabetic ESKD patients were included in this prospective cohort study (male/female, 26/16; age, 59.5±0.7 years; HD duration, 31.2±4.6 months; diabetes mellitus duration, 174,6±7,8 months). The patients were divided into two groups: the 1st (main) group (n=22) was treated by combination of magnesium aspartate (0.5 g/day orally) by three 2-months’ courses/year and L-carnitine (1 g/day parenterally after each HD session) throughout the year; the 2nd (comparison) group (n=20) was only on the basic therapy. The observation time was 12 months. A complete echocardiography and ultrasound scanning of common carotid arteries (CCA) were performed. Results: During follow up period we found the reduction of the left atrium (p=0.008) and left ventricle (LV) diameters (p=0.004), decrease of LV mass index for 17,1% (p=0.005) and prevalence of pseudonormal and restrictive types of LV diastolic dysfunction for 53.3% (p=0.026), increase of the LV ejection fraction for 5.4% (p=0.004), and decrease the mean pulmonary artery pressure for 13% (p=0.009) in the main group. The annual incidence of both mitral and aortic valve calcification in the 2nd group was 10%, in the 1st group – 0%. After 12 months of treatment, increase of the CCA intima-media thickness (p=0.23) was recorded in the comparison group only. Conclusions: The combine use of magnesium and L-carnitine as part of a 12-month complex therapy provides an effective reduction ofLV hypertrophy, improves its systolic and diastolic function, reduces pulmonary hypertension, and prevents the progression of cardiac valve calcification and atherosclerotic damage.
References
Bikbov B, Purcell CA, Levey AS, Smith M, Abdoli A, Abebe M, et al. Global, regional, and national burden of chronic kidney disease, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet, 2020; 395(1025):709-733. doi.org/10.1016/S0140-6736(20)30045-3
Saeedi P, Petersohn I, Salpea P, Bright D, Williams R, Unwin N, et al. Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: Results from the International Diabetes Federation Diabetes Atlas, 9th edition. Diabetes Res Clin Pract, 2019;11(157):107843. doi: 10.1016/j.diabres.2019.107843
Al-Hajji AA, Alsubaie HA, Albaqshi HT, Al-Hajji HI, AlEssa FM, Abu Ali BM, et al. Cardiovascular disease-related mortality risk in end stage renal disease and type 2 diabetes: A systematic review. J Family Med Prim Care, 2020;9(7):3195-3199. doi: 10.4103/jfmpc.jfmpc_244_20.
Menon V, Gul A, Sarnak MJ. Cardiovascular risk factors in chronic kidney disease. Kidney Int, 2005;68(4):1413-1418. doi: 10.1111/j.1523-1755.2005.00551.x.
Kyyak YuH., Kyyak HYu, Barnett OYu. Cpetsyfichnist diabetychnoi kardiomiopatii za naiavnosti komorbidnykh sertsevo-sudynnykh zakhvoriuvan: kliniko-ultrastrukturni doslidzhennia [Specifics of diabetic cardiomyopathy in the cases of concomitant cardiovascular diseases:clinical and ultrastructural examinations]. Mizhnar. Endokr. Zhurnal, 2016;5:33-38. doi: 10.22141/2224-0721.5.77.2016.78751 In Ukrainian.
Serhiienko V.O., Serhiienko O.O. Diabetychna kardiomiopatiia: epidemiolohiia, etiolohiia ta patohenez [Diabetic cardiomyopathy: epidemiology, etiology and pathogenesis]. Mizhnar. Endokr. Zhurnal, 2020;16(4) doi: 10.22141/2224-0721.16.4.2020.208488 In Ukrainian.
Nishimura M, Hashimoto T, Kobayashi H, Fukukda T, Okino K, Yamamoto N, et al. Possible involvement of TNF-alpha in left ventricular remodeling in hemodialysis patients. J Nephrol, 2003;16(5):641-649. doi: https://www.ncbi.nlm.nih.gov/pubmed/14733409
Talari HR, Zakizade M, Soleimani A, Bahmani F, Ghaderi A, Mirhosseini N, et al. Effects of magnesium supplementation on carotid intima-media thickness and metabolic profiles in diabetic haemodialysis patients: a randomised, double-blind, placebo-controlled trial. Br J Nutr, 2019;121(7):809-817. doi: 10.1017/S0007114519000163.
Chen W, Fitzpatrick J, Monroy-Trujillo JM, Melamed ML, Parekh RS, Bushinsky DA. Diabetes Mellitus Modifies the Associations of Serum Magnesium Concentration With Arterial Calcification and Stiffness in Incident Hemodialysis Patients. Kidney International Reports, 2019;4:806–813. doi: https://doi.org/10.1016/j.ekir.2019.03.003
Khaniukov OO, Smolianova OV. The role of carnitine in the regulation of energy metabolism and modulation of the course of cardiovascular diseases and diabetes mellitus. Arterialna hipertenziia, 2020;13(2-3):11-20. doi: 10.22141/2224-1485.13.2-3.2020.205334 In Ukrainian
King DE. Inflammation and elevation of C-reactive protein: does magnesium play a key role? Magnes Res, 2009;22(2):57-59. https://europepmc.org/article/med/19658273
Sakurabayashi T, Takaesu Y, Haginoshita S, Takeda T, Aoike I, Miyazaki S, et al. Improvement of myocardial fatty acid metabolism through L-carnitine administration to chronic hemodialysis patients. Am J Nephrol, 1999;19(4):480-484. doi: 10.1159/000013502.
Matsumoto Y, Sato M, Ohashi H, Araki H, Tadokoro M, Osumi Y, et al. Effects of L-carnitine supplementation on cardiac morbidity in hemodialyzed patients. Am J Nephrol, 2000;20:201–207. doi:10.1159/000013584
Sakurabayashi T, Miyazaki S, Yuasa Y, Sakai S, Suzuki M, Takahashi S, et al. L-carnitine supplementation decreases the left ventricular mass in patients undergoing hemodialysis. Circ J, 2008;72:926–931. doi: 10.1253 / circj.72.926.
Mitsopoulos E, Griveas I, Zanos S, Anagnostopoulos K, Giannakou A, Pavlitou A, et al. Increase in serum magnesium level in haemodialysis patients receiving sevelamer hydrochloride. Int Urol Nephrol, 2005;37(2):321-328. doi: 10.1007 / s11255-004-7135-5.
Kikuchi K, Tanaka H, Gima M, Kashiwagi Y, Shida H, Kawamura Y, Hasebe N. Abnormalities of magnesium (Mg) metabolism and therapeutic significance of Mg administration in patients with metabolic syndrome, type 2 diabetes, heart failure and chronic hemodialysis. Clin Calcium, 2012;22(8):1217-1226. https://pubmed.ncbi.nlm.nih.gov/22846358/
Turgut F, Kanbay M, Metin MR, Uz E, Akcay A, Covic A. Magnesium supplementation helps to improve carotid intima media thickness in patients on hemodialysis. Int Urol Nephrol, 2008;40. https://link.springer.com/article/10.1007/s11255-008-9410-3
Sakaguchi Y, Shoji T, Hayashi T, Suzuki A, Shimizu M, Mitsumoto K, et al. Hypomagnesemia in Type 2 Diabetic Nephropathy: A Novel Predictor of End-Stage Renal Disease. Diabetes Care, 2012:4. doi.org/10.2337/dc12-0226
Ikee R. Cardiovascular disease, mortality, and magnesium in chronic kidney disease: growing interest in magnesium-related interventions. Renal Replacement Therapy, 2018;4. https://rrtjournal.biomedcentral.com/articles/10.1186/s41100-017-0142-7
Selim GS, Spasovski G, Tozija L. Hypomagnesemia and Cause-specific Mortality in Hemodialysis Patients: 5-year follow-up Analysis. IJAO, 2017;7. https://doi.org/10.5301/ijao.5000611
Lee Sh, Ryu J-H, Kim S-J, Ryu D-R, Kang D-H, Choi KB. The Relationship between Magnesium and Endothelial Function in End-Stage Renal Disease Patients on Hemodialysis. Yonsei Med J, 2016;57(6):1446-1453. doi: 10.3349 / ymj.2016.57.6.1446
Ogawa Ch, Tsuchiya K, Maeda K. High serum magnesium levels are associated with favorable prognoses in diabetic hemodialysis patients, retrospective observational study. PloS One, 2020;9. doi:10.1371 / journal.pone.0238763
Susla OB, Litovkina ZI, Bushtynska OV. Strukturno-funktsionalni zminy sertsia u khvorykh na diabetychnu nefropatiiu, yaki perebuvaiut na khronichnomu hemodializi [Structural and functional changes of the heart in patients with diabetic nephropathy undergoing hemodialysis]. Ukr J Nephr Dial, 2019;4(64):39-48. doi: https://doi.org/10.31450/ukrjnd.4(64).2019.06in Ukrainian
Susla O, Litovkina Z. Cardiovascular features of chronic inflammation and endothelial dysfunction in patients with diabetic nephropathy on programmed hemodialysis. Journal of Education, Health and Sport, 2020; 10(10):144-157. https://zenodo.org/record/4263238
Argani H, Rahbaninoubar M, Ghorbanihagjo A. Golmohammadi Z, Rashtchizadeh N. Effect of L-Carnitine on the Serum Lipoproteins and HDL-C Subclasses in Hemodialysis Patients. Nephron Clin Pract, 2005;101:c174–c179. doi.org/10.1159/000087411
Kamei Y, Kamei D, Tsuchiya K, Mineshima M, Nitta K. Association between 4-year all-cause mortality and carnitine profile in maintenance hemodialysis patients. PLoS One, 2018;13(8):e0201591. doi: 10.1371/journal.pone.0201591
Nishimura M, Tokoro T, Takatani T, Sato N, Nishida M, Hashimoto T, et al. Effects of intravenous L-carnitine on myocardial fatty acid imaging in hemodialysis patients: responders or non-responders to L-carnitine. SpringerPlus, 2015;4(353). doi: 10.1186 / s40064-015-1119-z
Fukami K, Yamagishi SI, Sakai K, Nasu M, Okuda S. Effects of switching from oral administration to intravenous injection of l-carnitine on lipid metabolism in hemodialysis patients. Clin Kidney J, 2014;7(5):470-474. doi: 10.1093/ckj/sfu082.
Lang, RM, Badano LP, Mor-Avi V, Afilalo J, Armstrong, A, Ernande L, et al. Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc Echocardiogr, 2015;28(1):1-39. doi: https://doi.org/10.1016/j.echo.2014.10.003
Nagueh SF, Smiseth OA,. Appleton CP, Byrd III BF, Dokainish H, Edvardsen T, et al. Recommendations for the evaluation of left ventricular diastolic function by echocardiography: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc Echocardiogr, 2016;29(4):277-314. doi: https://doi.org/10.1016/j.echo.2016.01.011
Baumgartner H, Hung J, Bermejo J. Echocardiographic assessment of valve stenosis: EAE/ASE recommendations for clinical practice. J. Am. Soc. Echocardiogr, 2009; 22, (1):1-23. doi: 10.1016 / j.echo.2008.11.029.
Vylkenskhof U, Kruk Y. Spravochnyk po ekhokardyohrafyy: perevod s nemetskoho. М.: Med Lyt, 2008. 240 s. [In Russian].
Yilmaz R, Altun B, Kahraman S, Ozer N, Akinci D, Turgan C. Impact of amlodipine or ramipril treatment on left ventricular mass and carotid intima-media thickness in nondiabetic hemodialysis patients. Ren Fail, 2010;32(8):903-12. doi: 10.3109/0886022X.2010.502276.
Lin Y-C, Lin J-W, Wu M-S, Chen K-C, Peng C-C, Kang Y-N. Effects of calcium channel blockers comparing to angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in patients with hypertension and chronic kidney disease stage 3 to 5 and dialysis: A systematic review and meta-analysis. PLoS One, 2017;12(12): e0188975. doi:10.1371/journal.pone.0188975
Abdallah E, Waked E, Nabil M, Abdel-Khalek A, Metwally A.Carotid intima media thickness, left ventricular hypertrophy and weekly averaged blood pressure in hemodialysis patients. J Egypt Soc Parasitol, 2011;41(1):141-54. https://pubmed.ncbi.nlm.nih.gov/21634250/
Herzog CA, Asinger RW, Berger AK, et al. Cardiovascular disease in chronic kidney disease. A clinical update from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int, 2011;80(6):572-588. doi:https://doi.org/10.1038/ki.2011.223
Lashutin SV, Kiabiya ST. Karnitin i khronicheskij gemodializ. Dializny`j al`manakh, 2006;2:179-201. [in Russian].
Katalinic L, Krtalic B, Jelakovic B, Basic-Jukic N. The Unexpected Effects of L-Carnitine Supplementation on Lipid Metabolism in Hemodialysis Patients. Kidney Blood Press Res, 2018;43(4):1113-1120. doi: 10.1159/000491807
Jakuszewski P, Czerwieńska B, Chudek J, Wiecek A. Which components of malnutrition-inflammation-atherosclerosis syndrome are more common in haemodialysis patients with diabetic nephropathy? Nephrology (Carlton), 2009;14(7):643-649. doi: 10.1111/j.1440-1797.2009.01096.x
Fukami K, Yamagishi SI, Sakai K, Kaida Y, Adachi T, Ando R, et al. Potential Inhibitory Effects of l-Carnitine Supplementation on Tissue Advanced Glycation End Products in Patients with Hemodialysis. Rejuvenation Res, 2013; 16(6): 460–466. doi: 10.1089/rej.2013.1459
Drosatos K, Schulze PC. Cardiac Lipotoxicity: Molecular Pathways and Therapeutic Implications. Current Heart Failure Reports, 2013;(10):109–121. https://link.springer.com/article/10.1007%2Fs11897-013-0133-0
Duranay M, Akay H, Yilmaz FM, Senes M,Tekeli N, Yucel D. Effects of L-carnitine infusions on inflammatory and nutritional markers in haemodialysis patients. Nephrol Dial Transplant, 2006;21:3211–3214. doi:10.1093/ndt/gfl356
Sada H, Kato A, Sumimoto R, Ohmori H, Ohdan. H. Effects of L-carnitine supplementation on nutritional, immunological, and cardiac parameters in hemodialysis patients: a pilot study. Renal Replacement Therapy, 2015;1(3). https://rrtjournal.biomedcentral.com/articles/10.1186/s41100-015-0004-0
Pooyandjoo М, Nouhi М, Shab-Bidar S, Djafarian K, Olyaeemanesh A.Vplyv L-karnitynu na znyzhennia masy tila v doroslykh: systematychnyi ohliad i metaanaliz randomizovanykh kontrolovanykh klinichnykh vyprobuvan. Endokrynolohiia, 2018;23(1):83-90. http://nbuv.gov.ua/UJRN/enkrl_2018_23_1_12 In Ukrainian.
Higuchi T, Abe M, Yamazaki T, Okawa E, Ando H, Hotta S. Levocarnitine Improves Cardiac Function in Hemodialysis Patients With Left Ventricular Hypertrophy: A Randomized Controlled Trial. American Journal of Kidney Diseases, 2016;67(2):260-270. https://doi.org/10.1053/j.ajkd.2015.09.010
Floege J. Magnesium in CKD: more than a calcification inhibitor? J Nephrol, 2015;28:269–277. doi: 10.1007/s40620-014-0140-6
Hamano N, Komaba H, Fukagawa M. Magnesium as a new player in CKD: too little is as bad as too much? Kidney Int, 2017;92(5):1034-1036. doi: 10.1016/j.kint.2017.05.032.
Kanbay M, Goldsmith D, Uyar ME, Turgut F, Covic A. Magnesium in Chronic Kidney Disease: Challenges and Opportunities. Blood Purif , 2010;29:280–292. doi.org/10.1159/000276665
Ureña-Torres P, D'Marco L, Raggi P, García-Moll X, Brandenburg V, Mazzaferro S, et al. Valvular heart disease and calcification in CKD: more common than appreciated. Nephrol Dial Transplant, 2020;35(12):2046-2053. doi: 10.1093/ndt/gfz133.
Susla OB, Litovkina ZI. Metabolichni faktory sertsevo-sudynnoho ryzyku u khvorykh iz diabetychnoiu nefropatiieiu na prohramnomu hemodializi [Metabolic factors of cardiovascular risk in patients with diabetic nephropathy who undergo programmed hemodyalisis]. Visnyk naukovykh doslidzhen, 2018;4(93):55-60. doi 10.11603/2415-8798.2018.4.9813 [in Ukrainian].
Susla AB, Lytovkyna ZY, Susla BA, Danіlyv SV. Hypomahnyemyia y strukturno-funktsyonalnoe sostoianye myokarda levoho zheludochka u bolnіkh s dyabetycheskoi nefropatyei na prohrammnom hemodyalyze. Materyal VI Konhressa Assotsyatsyy Nefrolohov Novіkh Nezavysymіkh Hosudarstv 2020; 7-8 dekabria, Mynsk, Belarus; 2020. https://nephro-belarus.org/images/Sbornik-tezisov-VI-Kongressa-Associacii-nefrologov-NNG.pdf [In Russian].
Downloads
Published
How to Cite
Issue
Section
License
The periodical offers access to content in the Open Access system under the Creative Commons Attribution-NonCommercial-ShareAlike 4.0
Stats
Number of views and downloads: 258
Number of citations: 0
